Ribavirin
- TRADE NAMES: Copegus (Roche); Rebetol (Schering-Plough); Rebetron (Schering); Viramid; Virazid; Virazole (Valeant)
- INDICATIONS: Respiratory syncytial viral infections
- CLASS: Antiviral; nucleoside analog
- HALF-LIFE: 24 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abacavir, Azathioprine, Didanosine, Emtricitabine, Interferon Alfa, PEG-Interferon, Stavudine, Zidovudine
PREGNANCY CATEGORY: X
Investigated for treating COVID-19.
[INH] = Inhalation; [O] = Oral.
Rebetron is ribavirin and interferon.
RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 03/13/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric